Silence Therapeutics (SLN) Return on Sales (2020 - 2026)

Silence Therapeutics' Return on Sales history runs 7 years deep, the most recent figure standing at 0.35% for Q1 2026.

• In Q1 2026, Return on Sales rose 165.0% year-over-year to 0.35%; the TTM figure through Mar 2026 stood at 0.93% (down 91.0% YoY), while the FY2025 annual figure was 1.6%, down 159.0% from the prior year.
• Return on Sales came in at 0.35% for Q1 2026 at Silence Therapeutics, up from 3.78% in the prior quarter.
• In the past five years, Return on Sales ranged from a high of 0.0% in Q4 2024 to a low of 3.78% in Q4 2025.
• A 5-year average of 0.57% and a median of 0.04% in 2023 frame the typical range for Return on Sales.
• Across the five-year window, Return on Sales jumped 3138 bps in 2022 and sank 378 bps in 2025, its largest moves.
• Silence Therapeutics' Return on Sales stood at 0.03% in 2022, then slumped by 126 bps to 0.07% in 2023, then jumped by 107 bps to 0.0% in 2024, then plunged by 77830 bps to 3.78% in 2025, then jumped by 91 bps to 0.35% in 2026.
• According to Business Quant data, Return on Sales over the past three periods registered 0.35%, 3.78%, and 1.32% for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison